BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 22152281)

  • 1. Pitavastatin: an overview.
    Saito Y
    Atheroscler Suppl; 2011 Nov; 12(3):271-6. PubMed ID: 22152281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
    da Silva PM
    Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pitavastatin: clinical effects from the LIVES Study.
    Teramoto T
    Atheroscler Suppl; 2011 Nov; 12(3):285-8. PubMed ID: 22152283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New evidence on pitavastatin: efficacy and safety in clinical studies.
    Teramoto T; Shimano H; Yokote K; Urashima M
    Expert Opin Pharmacother; 2010 Apr; 11(5):817-28. PubMed ID: 20201733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.
    Sansanayudh N; Wongwiwatthananukit S; Putwai P; Dhumma-Upakorn R
    Ann Pharmacother; 2010 Mar; 44(3):415-23. PubMed ID: 20179259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pitavastatin - results from phase III & IV.
    Betteridge J
    Atheroscler Suppl; 2010 Dec; 11(3):8-14. PubMed ID: 21193153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pitavastatin - from clinical trials to clinical practice.
    Masana L
    Atheroscler Suppl; 2010 Dec; 11(3):15-22. PubMed ID: 21193154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study).
    Yokote K; Bujo H; Hanaoka H; Shinomiya M; Mikami K; Miyashita Y; Nishikawa T; Kodama T; Tada N; Saito Y
    Atherosclerosis; 2008 Dec; 201(2):345-52. PubMed ID: 18472103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C.
    Teramoto T
    Expert Opin Pharmacother; 2012 Apr; 13(6):859-65. PubMed ID: 22332608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Searching the place of pitavastatin in the current treatment of patients with dyslipidemia.
    Barrios V; Escobar C; Zamorano JL
    Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1597-612. PubMed ID: 24215190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pitavastatin: a new HMG-CoA reductase inhibitor.
    Wensel TM; Waldrop BA; Wensel B
    Ann Pharmacother; 2010 Mar; 44(3):507-14. PubMed ID: 20179258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial.
    Saku K; Zhang B; Noda K;
    Circ J; 2011; 75(6):1493-505. PubMed ID: 21498906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study.
    Kurogi K; Sugiyama S; Sakamoto K; Tayama S; Nakamura S; Biwa T; Matsui K; Ogawa H;
    J Cardiol; 2013 Aug; 62(2):87-94. PubMed ID: 23672789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals.
    Saito Y
    Vasc Health Risk Manag; 2009; 5():921-36. PubMed ID: 19997573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.
    Yee LL; Wright EA
    Clin Ther; 2011 Aug; 33(8):1023-42. PubMed ID: 21816477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pitavastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
    Ahmad H; Cheng-Lai A
    Cardiol Rev; 2010; 18(5):264-7. PubMed ID: 20699675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.